Prospective Randomised Phase-II Trial of Ipilimumab/Nivolumab versus Standard of Care in non-clear cell Renal Cell ...
Non-clear cell renal cell cancers (nccRCCs) are a heterogeneous group of more than 20 different entities, but are rarely included in large, randomized trials. Tyrosine kinase inhibitors with or without immune checkpoint inhibition are considered as a …